Table of contents
Chapter 1 Research Methodology
1.1 Information Procurement
1.2 Information or Data Analysis
1.3 Market Formulation & Validation
Chapter 2 Executive Summary
2.1 Competition Milieu
2.2 Market Snapshot
2.3 Segment Outlook
Chapter 3 Market Variables, Trends, & Scope
3.1 Penetration & Growth Prospect Mapping for Therapy Type, 2020
3.2 T-Cell Therapy – Market Dynamics
3.2.1 Market driver analysis
3.2.1.1 Rising investment in adoptive T cell transfer approaches of disease treatment
3.2.1.2 Growing competition among market players
3.2.1.3 Approval of Kymriah and Yescarta across various countries
3.2.1.4 Developments in CAR T-cell therapy for solid tumors
3.2.1.5 Technological advancements in manufacturing process
3.2.2 Market restraint analysis
3.2.2.1 Regulatory, scientific, and ethical challenges associated with gene therapy
3.2.2.1 High prices of therapies
3.2.2.2 CAR T limitations
3.2.3 Opportunity analysis
3.2.3.1 Facility expansion for cell and gene therapies
3.2.3.1 Rising global financings in gene and cell therapy arena
3.2.3.2 Ongoing developments in viral & non-viral vector manufacturing arena
3.3 Regulatory Landscape
3.3.1 Current and potential future approvals
3.3.2 Frameworks for risk mitigation and safety monitoring
3.3.3 Regulatory framework, by geography
3.3.3.1 U.S.
3.3.3.2 Europe
3.3.3.3 China
3.3.3.4 Japan
3.4 Pricing and Payment Models for Adoptive Cellular Therapies (ACT)
3.4.1 Insurance coverage
3.4.2 Value-based price benchmarks
3.4.3 Alternate payment strategies
3.5 Patent Landscape
3.6 Deals, Funding’s, Partnerships and Collaborations
3.6.1 Licensing deals
3.6.2 Merger & acquisition deals
3.6.3 Collaboration & partnerships
3.7 Pipeline Analysis
3.7.1 Clinical trial landscape
3.8 Geographic Mapping of Companies
3.9 Competitive Landscape for CD19directed CART Therapies and Other T-cell therapies
3.10 T-cell Therapy Market – SWOT Analysis, by Factor (Political & Legal, Economic, and Technological)
3.10.1 Political landscape
3.10.2 Economic landscape
3.10.3 Social landscape
3.10.4 Technology landscape
3.11 Industry Analysis – Porter’s
3.11.1 Supplier bargaining power
3.11.2 Buyer bargaining power
3.11.3 Substitution threat
3.11.4 Threat from new entrant
3.11.5 Competitive rivalry
Chapter 4 T-cell Therapy Market: Modality Estimates & Trend Analysis
4.1 T-cell Therapy Market: Modality Movement Analysis
4.2 Research
4.2.1 Global research-based T-cell therapy market, 2018 – 2030 (USD Million)
4.3 Commercialized
4.3.1 Global commercial T-cell therapy market, 2018 – 2030 (USD Million)
Chapter 5 T-cell Therapy Market Categorization: Therapy Type Estimates & Trend Analysis
5.1 T-cell Therapy Market: Therapy Type Movement Analysis
5.2 CAR T-cell Therapy
5.2.1 Global CAR T-cell Therapy market, 2018 – 2030 (USD Million)
5.3 T Cell Receptor (TCR)-based
5.3.1 Global T Cell Receptor (TCR)-based therapy market, 2018 – 2030 (USD Million)
5.4 Tumor Infiltrating Lymphocytes (TIL)-based
5.4.1 Global Tumor Infiltrating Lymphocytes (TIL)-based therapy market, 2018 – 2030 (USD Million)
Chapter 6 T-cell Therapy Market Categorization: Indication Estimates & Trend Analysis
6.1 T-cell Therapy Market: Indication Movement Analysis
6.2 Hematologic Malignancies
6.2.1 Global T-cell therapy market for hematologic malignancies, 2018 – 2030 (USD Million)
6.2.2 Lymphoma
6.2.2.1 Global T-cell therapy market for lymphoma, 2018 – 2030 (USD Million)
6.2.3 Leukemia
6.2.3.1 Global T-cell therapy market for leukemia, 2018 – 2030 (USD Million)
6.2.4 Myeloma
6.2.4.1 Global T-cell therapy market for myeloma, 2018 – 2030 (USD Million)
6.3 Solid Tumors
6.3.1 Global T-cell therapy market for solid tumors, 2018 – 2030 (USD Million)
6.3.2 Melanoma
6.3.2.1 Global T-cell therapy market for melanoma, 2018 – 2030 (USD Million)
6.3.3 Brain & Central Nervous System
6.3.3.1 Global T-cell therapy market for brain & central nervous system, 2018 – 2030 (USD Million)
6.3.4 Liver cancer
6.3.4.1 Global T-cell therapy market for liver cancer, 2018 – 2030 (USD Million)
6.3.5 Others
6.3.5.1 Global T-cell therapy market for other cancer forms, 2018 – 2030 (USD Million)
6.4 Others
6.4.1 Global T-cell therapy market for others, 2018 – 2030 (USD Million)
Chapter 7 T-cell Therapy Market Categorization: Regional Estimates & Trend Analysis, by Modality, Therapy Type & Indication
7.1 North America
7.1.1 SWOT Analysis
7.1.1.1 North America T-cell therapy market estimates and forecasts, 2018 – 2030 (USD Million)
7.1.2 U.S.
7.1.2.1 Key country dynamics
7.1.2.2 Target disease prevalence
7.1.2.3 Competitive scenario
7.1.2.4 Regulatory framework
7.1.2.5 Reimbursement scenario
7.1.2.6 U.S. T-cell therapy market estimates and forecasts, 2018 – 2030 (USD Million)
7.1.3 Canada
7.1.3.1 Key country dynamics
7.1.3.2 Target disease prevalence
7.1.3.3 Competitive scenario
7.1.3.4 Regulatory framework
7.1.3.5 Reimbursement scenario
7.1.3.6 Canada T-cell therapy market estimates and forecasts, 2018 – 2030 (USD Million)
7.2 Europe
7.2.1 SWOT Analysis
7.2.1.1 Europe T-cell therapy market estimates and forecasts, 2018 – 2030 (USD Million)
7.2.2 Germany
7.2.2.1 Key country dynamics
7.2.2.2 Target disease prevalence
7.2.2.3 Competitive scenario
7.2.2.4 Regulatory framework
7.2.2.5 Reimbursement scenario
7.2.2.6 Germany T-cell therapy market estimates and forecasts, 2018 – 2030 (USD Million)
7.2.3 UK
7.2.3.1 Key country dynamics
7.2.3.2 Target disease prevalence
7.2.3.3 Competitive scenario
7.2.3.4 Regulatory framework
7.2.3.5 Reimbursement scenario
7.2.3.6 UK T-cell therapy market estimates and forecasts, 2018 – 2030 (USD Million)
7.2.4 France
7.2.4.1 Key country dynamics
7.2.4.2 Target disease prevalence
7.2.4.3 Competitive scenario
7.2.4.4 Regulatory framework
7.2.4.5 Reimbursement scenario
7.2.4.6 France T-cell therapy market estimates and forecasts, 2018 – 2030 (USD Million)
7.2.5 Italy
7.2.5.1 Key country dynamics
7.2.5.2 Target disease prevalence
7.2.5.3 Competitive scenario
7.2.5.4 Regulatory framework
7.2.5.5 Reimbursement scenario
7.2.5.6 Italy T-cell therapy market estimates and forecasts, 2018 – 2030 (USD Million)
7.2.6 Spain
7.2.6.1 Key country dynamics
7.2.6.2 Target disease prevalence
7.2.6.3 Competitive scenario
7.2.6.4 Regulatory framework
7.2.6.5 Reimbursement scenario
7.2.6.6 Spain T-cell therapy market estimates and f.orecasts, 2018 – 2030 (USD Million)
7.2.7 Denmark
7.2.7.1 Key country dynamics
7.2.7.2 Target disease prevalence
7.2.7.3 Competitive scenario
7.2.7.4 Regulatory framework
7.2.7.5 Reimbursement scenario
7.2.7.6 Denmark T-cell therapy market estimates and forecasts, 2018 – 2030 (USD Million)
7.2.8 Sweden
7.2.8.1 Key country dynamics
7.2.8.2 Target disease prevalence
7.2.8.3 Competitive scenario
7.2.8.4 Regulatory framework
7.2.8.5 Reimbursement scenario
7.2.8.6 Sweden T-cell therapy market estimates and forecasts, 2018 – 2030 (USD Million)
7.2.9 Norway
7.2.9.1 Key country dynamics
7.2.9.2 Target disease prevalence
7.2.9.3 Competitive scenario
7.2.9.4 Regulatory framework
7.2.9.5 Reimbursement scenario
7.2.9.6 Norway T-cell therapy market estimates and forecasts, 2018 – 2030 (USD Million)
7.2.10 Rest Of Europe T-Cell Therapy Market Estimates And Forecasts, 2018 – 2030 (USD Million)
7.3 Asia Pacific
7.3.1 SWOT analysis
7.3.1.1 Key Region Dynamics
7.3.1.2 Asia Pacific T-cell therapy market estimates and forecasts, 2018 – 2030 (USD Million)
7.3.2 Japan
7.3.2.1 Target disease prevalence
7.3.2.2 Competitive scenario
7.3.2.3 Regulatory framework
7.3.2.4 Reimbursement scenario
7.3.2.5 Japan T-cell therapy market estimates and forecasts, 2018 – 2030 (USD Million)
7.3.3 China
7.3.3.1 Target disease prevalence
7.3.3.2 Competitive scenario
7.3.3.3 Regulatory framework
7.3.3.4 Reimbursement scenario
7.3.3.5 China T-cell therapy market estimates and forecasts, 2018 – 2030 (USD Million)
7.3.4 India
7.3.4.1 Target disease prevalence
7.3.4.2 Competitive scenario
7.3.4.3 Regulatory framework
7.3.4.4 Reimbursement scenario
7.3.4.5 India T-cell therapy market estimates and forecasts, 2018 – 2030 (USD Million)
7.3.5 South Korea
7.3.5.1 Target disease prevalence
7.3.5.2 Competitive scenario
7.3.5.3 Regulatory framework
7.3.5.4 Reimbursement scenario
7.3.5.5 South Korea T-cell therapy market estimates and forecasts, 2018 – 2030 (USD Million)
7.3.6 Australia
7.3.6.1 Target disease prevalence
7.3.6.2 Competitive scenario
7.3.6.3 Regulatory framework
7.3.6.4 Reimbursement scenario
7.3.6.5 Austrlia T-cell therapy market estimates and forecasts, 2018 – 2030 (USD Million)
7.3.7 Thailand
7.3.7.1 Target disease prevalence
7.3.7.2 Competitive scenario
7.3.7.3 Regulatory framework
7.3.7.4 Reimbursement scenario
7.3.7.5 Thailand T-cell therapy market estimates and forecasts, 2018 – 2030 (USD Million)
7.3.8 Rest Of Asia Pacific T-Cell Therapy Market Estimates And Forecasts, 2018 – 2030 (USD Million)
7.4 Latin America
7.4.1 SWOT Analysis
7.4.2 Key Regional Dynamics
7.4.2.1 Latin America T-cell therapy market estimates and forecasts, 2018 – 2030 (USD Million)
7.4.3 Brazil
7.4.3.1 Target disease prevalence
7.4.3.2 Competitive scenario
7.4.3.3 Regulatory framework
7.4.3.4 Reimbursement scenario
7.4.3.5 Brazil T-cell therapy market estimates and forecasts, 2018 – 2030 (USD Million)
7.4.4 Mexico
7.4.4.1 Target disease prevalence
7.4.4.2 Competitive scenario
7.4.4.3 Regulatory framework
7.4.4.4 Reimbursement scenario
7.4.4.5 Mexico T-cell therapy market estimates and forecasts, 2018 – 2030 (USD Million)
7.4.5 Argentina
7.4.5.1 Target disease prevalence
7.4.5.2 Competitive scenario
7.4.5.3 Regulatory framework
7.4.5.4 Reimbursement scenario
7.4.5.5 Argentina T-cell therapy market estimates and forecasts, 2018 – 2030 (USD Million)
7.4.6 Rest Of Latam T-Cell Therapy Market Estimates And Forecasts, 2018 – 2030 (USD Million)
7.5 Middle East & Africa (MEA)
7.5.1 SWOT Analysis
7.5.2 KEY regional Dynamics
7.5.2.1 Middle East & Africa T-cell therapy market estimates and forecasts, 2018 – 2030 (USD Million)
7.5.3 South Africa
7.5.3.1 Target disease prevalence
7.5.3.2 Competitive scenario
7.5.3.3 Regulatory framework
7.5.3.4 Reimbursement scenario
7.5.3.5 Brazil T-cell therapy market estimates and forecasts, 2018 – 2030 (USD Million)
7.5.4 Saudi Arabia
7.5.4.1 Target disease prevalence
7.5.4.2 Competitive scenario
7.5.4.3 Regulatory framework
7.5.4.4 Reimbursement scenario
7.5.4.5 Saudi Arabia T-cell therapy market estimates and forecasts, 2018 – 2030 (USD Million)
7.5.5 UAE
7.5.5.1 Target disease prevalence
7.5.5.2 Competitive scenario
7.5.5.3 Regulatory framework
7.5.5.4 Reimbursement scenario
7.5.5.5 UAE T-cell therapy market estimates and forecasts, 2018 – 2030 (USD Million)
7.5.6 Kuwait
7.5.6.1 Target disease prevalence
7.5.6.2 Competitive scenario
7.5.6.3 Regulatory framework
7.5.6.4 Reimbursement scenario
7.5.6.5 Kuwait T-cell therapy market estimates and forecasts, 2018 – 2030 (USD Million)
7.5.7 Rest of MEA T-cell therapy market Estimates and Forecasts, 2018 – 2030 (USD Million)
Chapter 8 Competitive Landscape
8.1 Strategy Framework
8.2 Company Profiles
8.2.1 Novartis AG
8.2.1.1 Company overview
8.2.1.1.1 AveXis, Inc.
8.2.1.2 Financial performance
8.2.1.3 Product benchmarking
8.2.1.4 Strategic initiatives
8.2.2 Gilead Sciences
8.2.2.1 Company overview
8.2.1.1.1 Kite Pharma
8.2.2.2 Financial performance
8.2.2.3 Product benchmarking
8.2.2.4 Strategic initiatives
8.2.3 bluebird bio, Inc.
8.2.3.1 Company overview
8.2.3.2 Financial performance
8.2.3.3 Product benchmarking
8.2.3.4 Strategic initiatives
8.2.4 TCR2 Therapeutics Inc
8.2.4.1 Company overview
8.2.4.2 Financial performance
8.2.4.3 Product benchmarking
8.2.4.4 Strategic initiatives
8.2.5 Sorrento Therapeutics
8.2.5.1 Company overview
8.2.5.2 Product benchmarking
8.2.5.3 Strategic initiatives
8.2.6 Fate Therapeutics
8.2.6.1 Company overview
8.2.6.2 Financial performance
8.2.6.3 Product benchmarking
8.2.6.3 Strategic initiatives
8.2.7 Merck KGaA
8.2.7.1 Company overview
8.2.7.2 Financial performance
8.2.7.3 Product benchmarking
8.2.7.3 Strategic initiatives
8.2.8 Pfizer Inc.
8.2.8.1 Company overview
8.2.8.2 Financial performance
8.2.8.3 Product benchmarking
8.2.8.4 Strategic initiatives
8.2.9 Amgen
8.2.9.1 Company overview
8.2.9.2 Financial performance
8.2.9.3 Product benchmarking
8.2.9.4 Strategic initiatives
8.2.10 Celgene Corporation
8.2.10.1 Company overview
8.2.10.1.1 Juno Therapeutics
8.2.10.2 Financial performance
8.2.10.3 Product benchmarking
8.2.10.4 Strategic initiatives
